Evidence map›Paper›PMID 32488723›Full record

Trial reportJournal of endocrinological investigation2021

Micro- and macrovascular function in patients suffering from primary adrenal insufficiency: a cross-sectional case-control study.

M Müller, H Beiglböck, P Fellinger, Y Winhofer, A Luger, M Gschwandtner, A Willfort-Ehringer, R Koppensteiner, A Kautzky-Willer, M Krebs and 2 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of endocrinological investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

M MüllerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
H BeiglböckDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
P FellingerDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Y WinhoferDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
A LugerDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
M GschwandtnerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
A Willfort-EhringerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
R KoppensteinerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
A Kautzky-WillerDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
M KrebsDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. michael.krebs@meduniwien.ac.at.ORCID http://orcid.org/0000-0002-9265-7274
O SchlagerDivision of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
P WolfDivision of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Medical University of Vienna · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite adequate glucocorticoid (GC) and mineralocorticoid (MC) replacement therapy, patients suffering from primary adrenal insufficiency (AI) have an increased mortality, mainly due to cardiovascular diseases. Only little knowledge exists on the contribution of MC substitution to the cardiovascular risk. Therefore, this study investigates the impact of plasma renin concentration on parameters of micro- and macrovascular function.

methods26 patients with primary AI [female = 18, age: 51 (28; 78) years; BMI: 24 (18; 40) kg/m

resultsPWV was significantly higher in AI patients compared to controls [9.9 (5; 18.5) vs 7.3 (6.8; 7.7) m/s; p < .01], whereas no differences in microvascular function could be found. In Renin

conclusionsMicrovascular function is not impaired in patients with primary AI under adequate replacement therapy, although higher renin concentrations are associated with subclinical improvements. No relation between RAAS activity and macrovascular function is observed, while arterial stiffness might be increased in primary AI.

Indexed as

Carotid Intima-Media ThicknessMicrocirculationVascular StiffnessAddison DiseaseAdultAgedAustriaCardiovascular DiseasesCase-Control StudiesCross-Sectional StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisAddison’s diseaseGlucocorticoid replacement therapyMineralocorticoid replacement therapyRenin–angiotensin–aldosterone system

Identifiers

PMID32488723
PMCPMC7817592
OpenAlexW3028994611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.